Restricted accessResearch articleFirst published online 2026
Prediction of Specific Survival and Clinicopathological Impact of Somatic PALB2 Mutations and Pathogenic/Likely Pathogenic Variants (PV/LPV) in Breast Cancer: A Cohort Study of 81 Patients
PALB2 plays a crucial role in DNA repair by interacting with BRCA1 and BRCA2. To clarify the clinicopathological impact of somatic PALB2 variants, we analyzed tumor DNA extracted from formalin-fixed, paraffin-embedded (FFPE) breast cancer specimens from 81 patients. Targeted next-generation sequencing identified 1 514 variants, including 84 pathogenic or likely pathogenic variants and 9 genes with high mutation frequency; 2 deleterious somatic PALB2 variants were detected in 33% of samples. To explore transcriptional effects, we analyzed publicly available METABRIC mRNA expression data and found that elevated PALB2 mRNA levels were significantly associated with ER-/PR- tumors and poorer survival outcomes. High PALB2 expression remained an independent predictor of shorter overall survival and relapse-free survival. These findings highlight the clinical importance of somatic PALB2 mutations and the prognostic value of PALB2 expression in breast cancer.
HoughtonSCHankinsonSE. Cancer progress and priorities: breast cancer. Cancer Epidemiol Biomarkers Prev.2021;30(5):822–844. doi:10.1158/1055-9965.EPI-20-1193
2.
AcquahJBosson-AmedenuSEyiah-BediakoFBuabengAOuerfelliN. Modelling incidence and mortality cancer parameters with respect to GLOBOCAN 2020Age standardized world estimates. Heliyon. 2024;10(17):e36836. doi:10.1016/j.heliyon.2024.e36836
3.
AsiriSAsiriAUlahannanSAlanaziMHumranAHummadiA. Incidence rates of breast cancer by age and tumor characteristics among Saudi Women: recent trends. Cureus. 2020;12(1):e6664.
4.
SunYSZhaoZYangZN, et al.Risk factors and preventions of breast cancer. Int J Biol Sci.2017;13(11):1387–1397. doi:10.7150/ijbs.21635
5.
MomenimovahedZSalehiniyaH. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151–164.
6.
KotbAEl FakihRHanbaliA, et al.Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives. Exp Hematol.2018;67:1–9. doi:10.1016/j.exphem.2018.07.007
7.
Al-NumairNSTheyabAAlzahraniF, et al.Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy. Cancer Cell Int.2022;22(1):279. doi:10.1186/s12935-022-02696-7
8.
HawsawiYMShamsATheyabA, et al.The state-of-the-art of gene editing and its application to viral infections and diseases including COVID-19. Front Cell Infect Microbiol.2022;12:869889. doi:10.3389/fcimb.2022.869889
9.
MaximovPYAbderrahmanBHawsawiYM, et al.The structure-function relationship of angular estrogens and estrogen receptor alpha to initiate estrogen-induced apoptosis in breast cancer cells. Mol Pharmacol.2020;98(1):24–37. doi:10.1124/mol.120.119776
10.
HawsawiYMKhojaBAljaylaniAO, et al.Recent progress and applications of single-cell sequencing technology in breast cancer. Front Genet.2024;15:1417415. doi:10.3389/fgene.2024.1417415
11.
GarrawayLALanderES. Lessons from the cancer genome. Cell. 2013;153(1):17–37. doi:10.1016/j.cell.2013.03.002
12.
MacconaillLEGarrawayLA. Clinical implications of the cancer genome. J Clin Oncol.2010;28(35):5219–5228. doi:10.1200/JCO.2009.27.4944
13.
el-HazmiMAal-SwailemARWarsyASal-SwailemAMSulaimaniRal-MeshariAA. Consanguinity among the Saudi Arabian population. J Med Genet.1995;32(8):623–626. doi:10.1136/jmg.32.8.623
14.
AlzahraniORAlatwiHEAlharbiAA, et al.Identification and characterization of novel mutations in chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD) in Saudi subjects by whole-exome sequencing. Medicina (Kaunas). 2022;58(11).
15.
HawsawiYMAl-NumairNSSobahyTM, et al.The role ofBRCA1/2in hereditary and familial breast and ovarian cancers. Mol Genet Genomic Med.2019;7(9):e879. doi:10.1002/mgg3.879
16.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer.2000;83(10):1301–1308. doi:10.1054/bjoc.2000.1407
17.
EastonDFPharoahPDAntoniouAC, et al.Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med.2015;372(23):2243–2257. doi:10.1056/NEJMsr1501341
18.
DesmondAKurianAWGabreeM, et al.Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol.2015;1(7):943–951. doi:10.1001/jamaoncol.2015.2690
19.
OshiMGandhiSTokumaruY, et al.Conflicting roles of EGFR expression by subtypes in breast cancer. Am J Cancer Res. 2021;11(10):5094–5110.
20.
PernasSTolaneySM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol.2019;11:1758835919833519. doi:10.1177/1758835919833519
21.
Lao-OnURojviratPChansongkrowP, et al.c-Myc directly targets an over-expression of pyruvate carboxylase in highly invasive breast cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(3):165656. doi:10.1016/j.bbadis.2019.165656
22.
GalieM. RAS as supporting actor in breast cancer. Front Oncol.2019;9:1199. doi:10.3389/fonc.2019.01199
23.
SongCVTeoSHTaibNAYipCH. Surgery for BRCA, TP53 and PALB2: a literature review. Ecancermedicalscience. 2018;12:863. doi:10.3332/ecancer.2018.863
24.
RathSHawsawiYMAlzahraniFKhanMI. Epigenetic regulation of inflammation: the metabolomics connection. Semin Cell Dev Biol.2024;154(Pt C):355–363. doi:10.1016/j.semcdb.2022.09.008
25.
ButzHNagyPPappJ, et al.PALB2 Variants extend the mutational profile of Hungarian patients with breast and ovarian cancer. Cancers (Basel). 2023;15(17). doi:10.3390/cancers15174350
26.
XiaBShengQNakanishiK, et al.Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell.2006;22(6):719–729. doi:10.1016/j.molcel.2006.05.022
27.
ZhangFMaJWuJ, et al.PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol.2009;19(6):524–529. doi:10.1016/j.cub.2009.02.018
28.
AntoniouACFoulkesWDTischkowitzM. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(17):1651–1652. doi:10.1056/NEJMoa1400382
29.
ErkkoHXiaBNikkilaJ, et al.A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316–319. doi:10.1038/nature05609
30.
JanatovaMKleiblZStribrnaJ, et al.ThePALB2Gene is a strong candidate for clinical testing inBRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiol Biomarkers Prev.2013;22(12):2323–2332. doi:10.1158/1055-9965.EPI-13-0745-T
31.
RahmanNSealSThompsonD, et al.PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet.2007;39(2):165–167. doi:10.1038/ng1959
32.
YangXRDeviBCRSungH, et al.Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia. Breast Cancer Res Treat.2017;165(3):687–697. doi:10.1007/s10549-017-4356-8
33.
LiYTJiangWHWangXW, et al.PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China. Eur J Med Res.2015;20:85. doi:10.1186/s40001-015-0182-9
34.
CybulskiCKluzniakWHuzarskiT, et al.Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol.2015;16(6):638–644. doi:10.1016/S1470-2045(15)70142-7
35.
DengMChenHHZhuX, et al.Prevalence and clinical outcomes of germline mutations inBRCA1/2 and PALB2genes in 2769 unselected breast cancer patients in China. Int J Cancer.2019;145(6):1517–1528. doi:10.1002/ijc.32184
36.
YangXLeslieGDoroszukA, et al.Cancer risks associated with GermlinePALB2 pathogenic variants: an international study of 524 families. J Clin Oncol.2020;38(7):674–685. doi:10.1200/JCO.19.01907
37.
Duran-LozanoLMontalbanGBonacheS, et al.Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T. Breast Cancer Res Treat.2019;174(2):543–550. doi:10.1007/s10549-018-05094-8
38.
SirajAKBuRParvathareddySK, et al.PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients. Sci Rep.2023;13(1):7666. doi:10.1038/s41598-023-34693-9
39.
FordDEastonDFPetoJ. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57(6):1457–1462.
40.
SzklarczykDFranceschiniAWyderS, et al.STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res.2015;43(Database issue):D447–52. doi:10.1093/nar/gku1003
41.
ChoiYSimsGEMurphySMillerJRChanAP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688. doi:10.1371/journal.pone.0046688
42.
GyorffyBLanczkyAEklundAC, et al.An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat.2010;123(3):725–731. doi:10.1007/s10549-009-0674-9
43.
van de KampGHeemskerkTKanaarREssersJ. DNA double strand break repair pathways in response to different types of ionizing radiation. Front Genet.2021;12:738230. doi:10.3389/fgene.2021.738230
44.
FooTKXiaB. BRCA1-Dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer. Cancer Res.2022;82(18):3191–3197. doi:10.1158/0008-5472.CAN-22-1535
45.
CortesiLPiombinoCTossA. Germline mutations in other homologous recombination repair-related genes than BRCA1/2: Predictive or prognostic factors?J Pers Med. 2021;11(4). doi:10.3390/jpm11040245
46.
HamidABFrankLEBouleyRAPetreacaRC. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers. PLoS One. 2022;17(9):e0273736. doi:10.1371/journal.pone.0273736
47.
LeHPHeyerWDLiuJ. Guardians of the genome: BRCA2 and its partners. Genes (Basel). 2021;12(8).
48.
AlshammariFD. Breast cancer genetic susceptibility: with focus in Saudi Arabia. J Oncol Sci. 2019;5(1):6–12. doi:10.1016/j.jons.2019.02.001
49.
BarakehDHAljelaifyRBashawriY, et al.Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients. Oncotarget. 2021;12(7):686. doi:10.18632/oncotarget.27909
50.
AltinozAAl AmeriMQureshiWBoushNNairSCAbdel-AzizA. Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates. The Breast. 2020;53:119–124.
51.
PifferALuporsiEMathelinC. PALB2, gène majeur de susceptibilité au cancer du sein. Gynécologie Obstétrique Fertilité & Sénologie . 2018;46(10):701–705. doi:10.1016/j.gofs.2018.08.006
52.
SavvaCSadiqMSheikhO, et al.Werner syndrome protein expression in breast cancer. Clin Breast Cancer.2021;21(1):57–73.e7.e7. doi:10.1016/j.clbc.2020.07.013
53.
MurphyMPLeVineH. Alzheimer's disease and the amyloid-β peptide. J Alzheimer's Dis.2010;19(1):311–323. doi:10.3233/JAD-2010-1221
54.
EvansDGRKallionpääRAClementiM, et al.Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genet Med.2020;22(2):398–406. doi:10.1038/s41436-019-0651-6
55.
WangY-YHungACLoSHsiehY-CYuanS-SF. MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy. Cancer Lett.2021;514:1–11. doi:10.1016/j.canlet.2021.05.013
56.
MoslemiMVafaeiMKhaniP, et al.The prevalence of ataxia telangiectasia mutated (ATM) variants in patients with breast cancer patients: a systematic review and meta-analysis. Cancer Cell Int.2021;21(1):474. doi:10.1186/s12935-021-02172-8
57.
AlanaziMParineNRShaikJPAl NaeemAAldhaianS. Targeted sequencing of crucial cancer causing genes of breast cancer in Saudi patients. Saudi J Biol Sci.2020;27(10):2651–2659. doi:10.1016/j.sjbs.2020.05.047
58.
FangC-BWuH-TZhangM-LLiuJZhangG-J. Fanconi anemia pathway: Mechanisms of breast cancer predisposition development and potential therapeutic targets. Front Cell Dev Biol.2020;8. doi:10.3389/fcell.2020.00160
59.
RudlandPSPlatt-HigginsAMDaviesLM, et al.Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol.2010;176(6):2935–2947. doi:10.2353/ajpath.2010.090779
60.
MalikSSMasoodNAsifMAhmedPShahZUKhanJS. Expressional analysis of MLH1 and MSH2 in breast cancer. Curr Probl Cancer.2019;43(2):97–105. doi:10.1016/j.currproblcancer.2018.08.001
61.
TommiskaJSealSRenwickA, et al.Evaluation ofRAD50in familial breast cancer predisposition. Int J Cancer.2006;118(11):2911–2916. doi:10.1002/ijc.21738
62.
de OliveiraSFGanzinelliMChilàR, et al.Characterization of MTAP gene expression in breast cancer patients and cell lines. PLoS One. 2016;11(1):e0145647.
63.
PallesCMartinLDomingoE, et al.The clinical features of polymerase proof-Reading associated polyposis (PPAP) and recommendations for patient management. Fam Cancer.2022;21(2):197–209. doi:10.1007/s10689-021-00256-y
64.
MagrinLFanaleDBrandoC, et al.POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene. 2021;40(40):5893–5901. doi:10.1038/s41388-021-01984-2
65.
AgyemangKJohansenAMBarkerGW, et al.TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects. npj Breast Cancer. 2022;8(1):84. doi:10.1038/s41523-022-00446-6
SaidyBKotechaSButlerA, et al.PP1, PKA and DARPP-32 in breast cancer: a retrospective assessment of protein and mRNA expression. J Cell Mol Med.2021;25(11):5015–5024. doi:10.1111/jcmm.16447
